Abingworth promotes Bali Muralidhar to Managing Partner
News provided by
Share this article
Share this article
LONDON, Dec. 21, 2020 /PRNewswire/ Abingworth, the international investment group dedicated to life sciences, is pleased to announce the promotion of Bali Muralidhar MD PhD to Managing Partner, further strengthening the senior management of the firm. Bali is joining Tim Haines, Genghis Lloyd-Harris and Kurt von Emster in the Managing Partner role at the firm.
Tim Haines, Chairman & Managing Partner, said: Bali is an extremely talented investor who, since joining Abingworth, has brought new ideas that have made a significant and positive contribution to how we operate as a firm. Working closely with the team in the London, Boston and Menlo Park offices, he has also led a number of high-quality investments in the US and Europe, both public and private, which are already enhancing fund performance. His promotion is very well deserved, and we look forward to his cont
Search jobs 14-Dec-2020 TYK2 Identified as a Key Genetic Mechanism of Critical Illness in Covid-19 and as an Important Potential Target for Therapy
Findings published in
Nature support scientific rationale for Sareum’s SDC-1801 development programme in Covid-19 and its recent grant award from UKRI
Cambridge, UK, 14 December 2020 – Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, is pleased to note that a multi-centre analysis of DNA samples from patients with severe forms of Covid-19, including symptoms caused by the over-active inflammatory response (“cytokine storm”), has identified TYK2 as a key causative genetic mechanism and a potential target for therapy.